Aduro biotech, inc. (ADRO)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash Flows from Operating Activities
Net loss

-66,520

-82,372

-89,277

-91,472

-97,290

-95,357

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-84,133

-

-58,482

-22,864

-51,420

-39,209

-43,229

-48,480

-25,846

-17,014

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

0

3,678

-

3,320

2,923

2,472

2,003

1,483

1,154

898

634

459

365

290

240

0

0

0

Amortization of intangible assets

554

554

558

564

532

584

589

590

579

559

547

540

544

549

504

366

226

89

0

0

0

-

-

-

-

Impairment of property and equipment

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash lease expense

1,108

947

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discounts and amortization of premiums on marketable securities

1,611

1,670

1,638

1,404

1,207

1,067

723

395

-65

-621

-913

-1,283

-1,624

-1,831

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation

10,771

12,439

14,116

15,262

16,253

17,474

17,838

17,642

17,312

16,376

16,164

15,923

15,251

15,006

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

Excess tax benefit from stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

4,444

0

0

0

-

-

-

-

-

-

-

-

Loss from remeasurement of fair value of contingent consideration

0

-

-

-

-

635

0

0

0

-

-

-

-

400

0

0

0

-

-

-

-

-

-

-

-

Loss from remeasurement of fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26,077

26,361

26,518

9,562

566

0

0

0

Non-cash interest expense related to convertible promissory notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,380

0

0

0

Loss on disposal of property and equipment

-

-

-

-

-

-27

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income tax

-

-2,450

-2,367

-157

-160

-146

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

346

-11,695

222

322

6

11,048

-1,348

-2,335

937

-149

292

1,992

-2,103

-3,708

-2,091

323

1,336

1,693

3,023

948

511

2,796

0

0

0

Income tax receivable

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-2,171

-526

-46

-78

-373

-1,006

-1,498

-8,907

-4,238

-1,535

-8,094

-6,729

-7,070

-3,487

3,138

9,766

7,899

2,654

3,104

3,067

1,314

1,117

0

0

0

Accounts payable

-299

-799

968

853

56

533

-369

-2,482

-885

-1,206

-368

570

-2,633

-2,851

-4,018

-2,170

659

1,537

3,292

-59

2,480

1,681

0

0

0

Deferred revenue

-14,481

-14,758

-1,934

-291

758

288

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-15,080

-

-19,384

167,786

162,375

157,064

0

0

0

-

-

-

-

Accrued clinical trial and manufacturing expenses

1,732

1,730

259

-201

-1,009

-3,300

-2,733

-240

-1,162

924

-925

-9,677

-5,826

-745

2,397

9,697

5,911

2,172

2,981

2,614

2,662

2,460

0

0

0

Accrued expenses and other liabilities

1,771

-1,583

1,714

758

-1,569

-922

-2,585

1,255

4,991

4,049

8,231

6,217

2,404

8,981

4,215

362

3,379

1,638

2,576

4,191

4,616

1,461

0

0

0

Operating lease liabilities

-1,546

-334

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-62,164

-65,508

-44,532

-51,399

-59,367

-68,759

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash Flows from Investing Activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-85,555

-

-63,494

-44,805

139,918

154,810

182,875

189,129

15,868

19,365

0

0

0

Purchase of marketable securities

241,692

283,097

272,603

205,289

183,591

226,953

198,315

274,951

304,212

260,435

284,799

255,876

298,311

359,500

0

0

0

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

285,522

282,594

250,780

226,669

259,038

268,684

255,446

277,026

325,181

354,530

358,456

351,892

335,911

351,322

0

0

0

-

-

-

-

-

-

-

-

Purchase of property and equipment

884

1,260

1,541

1,922

670

2,365

3,779

4,526

6,532

5,154

7,790

14,804

23,263

23,887

19,837

11,545

3,225

2,174

2,120

1,680

970

782

0

0

0

Net cash provided by (used in) investing activities

42,946

-1,763

-23,333

19,495

74,818

39,407

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash Flows from Financing Activities
Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

13,869

-

-58,440

-318,501

-307,094

-297,988

-269,633

-1,680

-970

-782

0

0

0

Proceeds from issuance of common stock, net of offering costs

-

-

-

-

-

-

-

-

-

78,991

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Excess tax benefit from stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

4,444

0

0

0

-

-

-

-

-

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from issuance of convertible promissory note payable to related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

308

0

0

0

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

22,522

0

0

0

-

-

-

-

Proceeds from exercise of stock options

359

530

661

636

1,091

1,457

1,699

3,060

2,657

2,235

2,290

1,084

896

1,000

1,070

850

1,012

801

0

0

0

-

-

-

-

Net cash provided by financing activities

572

743

988

-2,518

-1,861

-1,495

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes

-87

-158

-269

-418

-755

-457

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

58,621

-

38,926

3,377

154,325

174,178

228,198

238,979

114,346

92,341

0

0

0

Net increase (decrease) in cash, cash equivalents and restricted cash

-18,733

-66,686

-67,146

-34,840

12,835

-31,304

-38,289

-69,414

-6,789

82,682

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental Disclosure of Non-Cash Investing and Financing Activities
Accrued offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Purchase of property and equipment in accounts payable and accrued liabilities

-

-

-

-

-409

331

2,257

3,223

3,421

2,790

-2,324

-3,469

-562

447

4,280

4,704

1,637

692

0

0

0

-

-

-

-

Reconciliation of Cash, Cash Equivalents and Restricted Cash
Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-83,008

-359,929

-12,851

31,000

141,440

426,428

129,244

110,924

0

0

0